Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Non-interventional, Prospective Study of Durvalumab in Unresectable Locally Advanced NSCLC in Routine Clinical Practice in Russia

NCT05456867 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT05456867
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05456867 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Non-interventional, Prospective Study of Durvalumab in Unresectable Locally Advanced NSCLC in Routine Clinical Practice in Russia
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Active, not recruiting
Start date
May 31, 2022
Completion date
November 30, 2026
Enrollment
250 (estimated)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

nsclc, non-small-cell lung carcinoma